


## AMENDMENTS TO THE CLAIMS

1(original). A compound of Formula (I)



wherein

$R^1$  is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl;

$R^2$  is hydrogen, -C(O) $R^{2a}$ , -C(O)-(CH<sub>2</sub>)<sub>n</sub>- $R^{2b}$ , or -(CH<sub>2</sub>)<sub>m</sub>- $R^{2c}$ , where n is 0, 1 or 2, m is 0, 1, 2 or 3,  $R^{2a}$  is (C<sub>1</sub>-C<sub>4</sub>)alkyl or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and  $R^{2b}$  and  $R^{2c}$  are -NH(C<sub>1</sub>-C<sub>4</sub>)alkyl, -N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, pyridinyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, phenyl, or piperidinyl;

$R^3$  is (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

X is carbonyl or methylene;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(original). The compound of Claim 1 wherein X is carbonyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3(original). The compound of Claim 1 wherein X is methylene; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

4(original). The compound of Claim 2 or 3 wherein  $R^2$  is -C(O)-(CH<sub>2</sub>)<sub>n</sub>- $R^{2b}$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5(original). The compound of Claim 4 wherein  $R^{2b}$  is pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

6(original). The compound of Claim 5 wherein  $R^{2b}$  is 3-pyridinyl or 4-pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7(original). The compound of Claim 2 or 3 wherein  $R^2$  is  $-(CH_2)_m-R^{2c}$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

8(original). The compound of Claim 7 wherein  $R^{2c}$  is  $-NH(C_1-C_4)alkyl$  or  $-N((C_1-C_4)alkyl)_2$ ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9(original). The compound of Claim 1 selected from the group consisting of  
 9-amino-5-ethyl-5H-phenanthridin-6-one;  
 9-amino-5-isopropyl-5H-phenanthridin-6-one;  
 9-Amino-5-isobutyl-5H-phenanthridin-6-one;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;  
 2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;  
 2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-isobutyramide;  
 N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;

9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one; and  
 9-benzylamino-5-ethyl-5H-phenanthridin-6-one;  
 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

10(original). The compound of Claim 4 selected from the group consisting of  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;  
 2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;  
 2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-  
 acetamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-  
 propionamide;  
 N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-acetamide;  
 N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-isobutyramide; and  
 N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;  
 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or  
 said salt.

11(original). The compound of Claim 7 selected from the group consisting of  
 9-benzylamino-5-ethyl-5H-phenanthridin-6-one; and  
 9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one;  
 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or  
 said salt.

12(previously presented). A pharmaceutical composition comprising a  
 compound of Claim 1 and a pharmaceutically acceptable excipient, diluent, or carrier.

13-16(cancelled).